In adults with type 2 diabetes, treatment with liraglutide or semaglutide is linked to a moderate decrease in the occurrence of serious heart problems and a small increase in survival time over 1.5...
Mechanism
Synthesis from 1 study
These drugs bind to receptors on artery walls and immune cells, turning down inflammation that causes dangerous buildups in blood vessels. This makes the buildups less likely to break open and trigger clots that cause heart attacks or strokes.
Most probable mechanism
The drugs bind to receptors on blood vessel walls and immune cells, which lowers inflammation inside artery walls, stabilizes fatty buildups, and reduces the chance of clots forming that cause heart attacks or strokes.
Liraglutide and semaglutide activate glucagon-like peptide-1 receptors on endothelial cells and macrophages in atherosclerotic plaques
Receptor activation suppresses nuclear factor kappa B signaling, reducing production of interleukin-6, tumor necrosis factor-alpha, and other pro-inflammatory cytokines
Decreased inflammation stabilizes atherosclerotic plaques by reducing matrix metalloproteinase activity and increasing collagen deposition in the fibrous cap
Plaque stabilization decreases the likelihood of rupture and subsequent thrombus formation in coronary or cerebral arteries
Reduced thrombus formation lowers the incidence of myocardial infarction, ischemic stroke, and cardiovascular death
Evidence from Studies
Supporting (1)
Community contributions welcome
Assessment of Cardiovascular Risk With Glucagon-Like Peptide 1 Receptor Agonists in Patients With Type 2 Diabetes Using an Alternative Measure to the Hazard Ratio
Contradicting (0)
Community contributions welcome
Gold Standard Evidence Needed
According to GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this specific claim, ordered from strongest to weakest evidence.